Celltrion expands its reach in Europe, securing marketing authorization from the European Commission (EC) for its denosumab biosimilar candidate (Stoboclo and Osenvelt) and its aflibercept biosimilar ...
The introduction of anti-VEGF agents has revolutionized the field of medical retina care by reducing rates of vision loss and ...
US FDA approves expanded label for Astellas’ Izervay for the treatment of geographic atrophy: Tokyo Friday, February 14, 2025, 09:00 Hrs [IST] Astellas Pharma Inc., a global lif ...
IZERVAY dosing approved beyond 12 months TOKYO, Feb. 12, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today ...
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the U.S. Food and Drug Administration (FDA) approved expanded U.S. Prescribing information for IZERVAYtm ...
The "Myopic Macular Degeneration (MMD) - Epidemiology Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.The report delivers an in-depth understanding of Myopic Macular ...
This study was limited as patients were not randomized and only eight patients had either geographic atrophy or choroidal neovascularization ... age-related macular degeneration (e.g., with ...
“Therefore, the choroid may be of biological significance in participants on atropine treatment given that there is clinical value in preventing choroidal thinning, irrespective of its association ...
This research team evaluated the effectiveness of switching patients to faricimab treatment by assessing their outcomes after 6 months of treatment in a retrospective chart review that included 102 ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果